VCAP-AMP-VECP + G-CSF

VCAP-AMP-VECP + G-CSF is a multi-agent combination chemotherapy regimen supported by granulocyte colony-stimulating factor (G-CSF), primarily used for the treatment of aggressive adult T-cell leukemia/lymphoma (ATL). The regimen consists of three alternating chemotherapy combinations: - **VCAP**: vincristine, cyclophosphamide, doxorubicin, prednisone - **AMP**: doxorubicin, ranimustine (a nitrosourea), prednisone - **VECP**: vindesine (a vinca alkaloid), etoposide, carboplatin, prednisone Each cycle is followed by administration of G-CSF to promote neutrophil recovery and reduce the risk of severe neutropenia. This dose-intensified approach aims to improve response rates and survival in aggressive ATL compared to standard regimens like CHOP. The mechanism involves cytotoxic effects on rapidly dividing malignant lymphocytes through multiple pathways including DNA damage and mitotic inhibition[1][2][3][4].

Other names

VCAP-AMP-VECP + G-CSFLSG15 protocolLSG-15 protocolLSG 15 protocolmLSG15 protocolmLSG-15 protocolmLSG 15 protocol